newsfilter
← Latest News
Business Wire·

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Granted Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfillipo Syndrome Type B (MPS IIIB) Biologics License Application Submission of TA-ERT for the